Liquidia Co. (NASDAQ:LQDA) Shares Sold by Findell Capital Management LLC

Findell Capital Management LLC cut its holdings in Liquidia Co. (NASDAQ:LQDA - Free Report) by 3.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,080,000 shares of the company's stock after selling 113,539 shares during the quarter. Liquidia makes up about 14.8% of Findell Capital Management LLC's holdings, making the stock its 2nd biggest holding. Findell Capital Management LLC owned 3.64% of Liquidia worth $36,221,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of LQDA. Steward Partners Investment Advisory LLC bought a new position in Liquidia during the 4th quarter valued at about $59,000. Summit Investment Advisors Inc. lifted its stake in shares of Liquidia by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock worth $78,000 after purchasing an additional 1,719 shares during the period. D. E. Shaw & Co. Inc. purchased a new position in Liquidia during the fourth quarter valued at approximately $142,000. EntryPoint Capital LLC purchased a new stake in shares of Liquidia in the fourth quarter worth $154,000. Finally, Bayesian Capital Management LP purchased a new stake in shares of Liquidia in the fourth quarter worth $163,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Stock Up 11.6%

Shares of LQDA traded up $1.85 during trading on Wednesday, reaching $17.84. 1,809,063 shares of the company traded hands, compared to its average volume of 1,009,400. Liquidia Co. has a twelve month low of $8.26 and a twelve month high of $18.12. The stock has a market cap of $1.53 billion, a PE ratio of -10.94 and a beta of 0.24. The stock has a 50-day simple moving average of $14.25 and a 200-day simple moving average of $13.21.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.03). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The company had revenue of $3.12 million for the quarter, compared to analyst estimates of $3.23 million. On average, equities research analysts predict that Liquidia Co. will post -1.51 EPS for the current year.

Insider Activity at Liquidia

In other Liquidia news, insider Rajeev Saggar sold 2,450 shares of the business's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $13.67, for a total transaction of $33,491.50. Following the completion of the transaction, the insider now owns 263,152 shares in the company, valued at $3,597,287.84. The trade was a 0.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Russell Schundler sold 5,964 shares of the business's stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $80,931.48. Following the transaction, the general counsel now owns 570,301 shares of the company's stock, valued at $7,738,984.57. This trade represents a 1.03% decrease in their position. The disclosure for this sale can be found here. Insiders sold 33,138 shares of company stock worth $450,233 in the last three months. 30.10% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Raymond James raised their target price on shares of Liquidia from $27.00 to $29.00 and gave the company a "strong-buy" rating in a research note on Friday, May 9th. Scotiabank reiterated an "outperform" rating on shares of Liquidia in a report on Monday, May 5th. Needham & Company LLC restated a "buy" rating and issued a $25.00 price target on shares of Liquidia in a report on Monday. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Liquidia in a research report on Monday. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $27.13.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).